Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Odyssey Health Inc (OP:ODYY)

0.0767 UNCHANGED
Streaming Delayed Price Updated: 1:52 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Odyssey Health Inc

< Previous 1 2 3 Next >
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.
Via ACCESSWIRE
Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.
Via ACCESSWIRE
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
Via ACCESSWIRE
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders
Via ACCESSWIRE
Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.
Via ACCESSWIRE
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
From Oragenics, Inc.
Via Business Wire
Odyssey Health Inc. Begins Trading on the OTCQB
Via ACCESSWIRE
Odyssey Health, Inc. Presents Concussion Treatment Data at the Military Health System Research Symposium - MHSRS
Via ACCESSWIRE
Odyssey Health, Inc. Presents Data at the Special Operations Medical Association - Scientific Assembly
Via ACCESSWIRE
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on creating unique, life-enhancing medical products, is developing a novel... 
Via TheNewswire.com
Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023
Via Investor Brand Network
Topics Animal Testing
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update
Via Investor Brand Network
Topics Intellectual Property
World Cup 2022 to Feature New Protocol to Respond to Suspected Concussions
Via Investor Brand Network
Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies
Via Investor Brand Network
Surgical Team in Spain Completes First-Ever Intestinal Transplant
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders
Via Investor Brand Network
Topics Intellectual Property
Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device
Via Investor Brand Network
Topics Intellectual Property
Study Finds Iron Causes Chronic Heart Failure in Heart Attack Survivors
Via Investor Brand Network
New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments
Via Investor Brand Network
Experts Concerned That Concussion Protocols Don’t Factor in Women
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Pleased with Safety Profile of Its PRV-002 Concussion Treatment
Via Investor Brand Network
Topics Intellectual Property
New Research Uncovers Racial Disparities in Treatment of Heart Failure
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Expedite Return to Work, Play Following Concussive Episode
Via Investor Brand Network
Topics Intellectual Property
New Experimental Drug May Reverse Brain Damage Caused by Concussions
Via Investor Brand Network
Odyssey Health, Inc. (ODYY) Updates Progress of its Concussion Drug Development Program; Communicating with the FDA for permission to start phase II clinical trial of its PRV-002 Drug Candidate
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Mitigate Short- and Long-Term Effects of mTBI
Via Investor Brand Network
Topics Intellectual Property
Researchers Develop AI Tool That Scans Retina, Detects Heart Disease in One Minute
Via Investor Brand Network
Topics Artificial Intelligence
Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.